脳炎ワクチンの世界市場 - 2022年～2029年

当レポートでは、世界の脳炎ワクチン市場について調査し、市場の概要とともに、ワクチンタイプ別、適応タイプ別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 脳炎ワクチン市場の調査手法と範囲

第2章 脳炎ワクチン市場-市場の定義と概要

第3章 脳炎ワクチン市場-エグゼクティブサマリー

• ワクチンタイプ別市場内訳
• 適応タイプ別市場内訳
• エンドユーザー別市場内訳
• 地域別市場内訳

第4章 脳炎ワクチン市場-市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 脳炎ワクチン市場-業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ

第6章 脳炎ワクチン市場-COVID-19分析

第7章 脳炎ワクチン市場-ワクチンタイプ別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、ワクチンタイプ別
• 市場魅力指数、ワクチンタイプ別
  • マウス脳由来の不活化ワクチン
  • 細胞培養由来の不活化ワクチン
  • 細胞培養由来の弱毒生ワクチン

第8章 脳炎ワクチン市場-適応タイプ別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、適応タイプ別
• 市場魅力指数、適応タイプ別
  • 日本脳炎
  • ダニ媒介性脳炎
  • 狂犬病脳炎
  • その他

第9章 脳炎ワクチン市場-エンドユーザー別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、エンドユーザー別
  • 市場魅力指数、エンドユーザー別
• 病院
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• 予防接種センター
• その他

第10章 脳炎ワクチン市場-地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）、地域別
  • 市場魅力指数、地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第11章 脳炎ワクチン市場-競合情勢

• 主な発展と戦略
• 企業シェア分析
• 製品のベンチマーク

第12章 脳炎ワクチン市場-企業プロファイル

• Pfizer Inc.
• Valneva SE
• Bharat Biotech
• BIKEN
• Sanofi Pasteur

第13章 脳炎ワクチン市場-DataM

Market Overview

The global encephalitis vaccines market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Encephalitis is a type of brain inflammation. A viral infection is the most common cause, but there are others. Encephalitis can also result in muddled thinking, seizures, or sensory or motor problems.

Market Dynamics

The global encephalitis vaccines market is the increasing awareness of encephalitis, and the growing prevalence of encephalitis is expected to drive the market growth.

The increasing awareness of encephalitis is expected to drive the global encephalitis vaccines market

The market is being boosted by increased government initiatives for vaccination programs. According to the Center for Vaccine Innovation and Access, the Indian Japanese encephalitis (JE) vaccine program has been a huge success. As of mid-2018, 65 percent of the districts with the vaccine had received routine JE immunisation. Approximately 156 million Indian children have been vaccinated against JE since 2006, and the country continues to self-fund the program by using the low-cost CD-JEV vaccine. In 2018 and 2019, an additional 38 districts have agreed to participate in JE vaccination campaigns. Moreover, in 2018, the CDC and PATH collaborated to convene a group of independent experts to review JE prevention and control successes, identify remaining scientific and operational issues that need to be addressed, discuss opportunities to strengthen JE vaccination programs and identify strategies and solutions to ensure JE control sustainability over the next decade.

The side effects associated with encephalitis vaccines are expected to hamper the market growth

The side effects or complications associated with encephalitis vaccines are expected to restrain the market's growth. For instance, after getting the JE vaccine, patients may experience pain, tenderness, redness, or swelling where the shot was given. Fever can strike at any time (more often in children). It's possible to get headaches or muscle aches (mainly in adults). Severe reactions to the JE vaccine are extremely rare, according to studies. Like any other medicine, a vaccine has a small chance of causing a severe allergic reaction, other serious injuries, or death. For the most part, Vaccines are simple procedures that protect communities from deadly diseases like tuberculosis, measles, and influenza. Patients may, however, experience side effects such as secondary encephalitis as a result of a vaccine. The Vaccine Adverse Event Reporting System has received over 1,100 reports of encephalitis (including brain stem encephalitis) (VAERS).

COVID-19 Impact Analysis

Due to the cold chain requirements, nearly all vaccine shipments are sent by air. Even though many vaccine shipments were initially hampered by national lockdown measures and airlines' grounding around the world following COVID-19, vaccine shipments recovered well in 2020. Shipping and logistics issues caused some JE vaccine deliveries to be delayed. Due to limited transportation capacity, freight costs skyrocketed, more than tripling due to competing demand. During the pandemic's peak, some charred flights were used to deliver the JE vaccine. While air freight analysts are quietly optimistic that air carriers will increasingly offer fixed rates, some carriers are raising their rates significantly due to ongoing sea freight congestion and a shift in high demand from sea freight to air freight. While carriers may offer fixed rates to UNICEF, UNICEF may be forced to pay premium rates to secure space as cargo space becomes scarce.

Furthermore, due to national regulatory authorities extending batch release procedures in response to the pandemic, the lead time for some JE vaccine procurement orders has increased beyond six months. Some JE manufacturers have reported lower sales and export numbers in 2020, which has had a financial impact on their liquidity (cash flow).

Segment Analysis

The Japanese encephalitis segment is expected to dominate the market growth in the forecast period

Japanese encephalitis is a virus that infects the brain and is spread by mosquito bites. It is most common in rural areas of Southeast Asia, the Pacific Islands, and the Far East, but it is extremely uncommon among travellers. The virus can be found in pigs and birds, and it is transmitted to mosquitos by biting infected animals. It is estimated that less than one in a million travellers will contract Japanese encephalitis in any given year. The World Health Organization (WHO) estimates that 68,000 cases of Japanese encephalitis occur each year around the world. People who live and work in rural areas, such as pig farms and rice fields, are particularly vulnerable. In approximately 75% of cases, children under 15 are involved. Over the forecast period, the Japanese encephalitis vaccine segment is expected to grow significantly. According to the World Health Organization, the annual number of clinical cases of JE in the world is estimated to be around 68000. Additionally, government initiatives for JE vaccination programmes are boosting the market. China and India have developed national immunisation plans that include mass vaccinations. Due to routine immunization, there is a high demand for JE vaccines in the market. As a result, one of the major growth drivers for the Japanese encephalitis vaccine segment during the forecast period will be the inclusion of vaccination against Japanese encephalitis in national immunization plans.

Geographical Analysis

Asia Pacific region is expected to hold the largest market share in the global encephalitis vaccines market

With an estimated 68 000 clinical cases per year, JEV is the most common cause of viral encephalitis in many Asian countries. Although symptomatic Japanese encephalitis (JE) is uncommon, the case fatality rate among encephalitis patients can reach 30%. Japanese encephalitis is a disease that primarily affects Asian countries. The disease has no known cure. As a result, organizations like UNICEF, WHO, and Gavi are focusing on vaccines to prevent the disease from spreading. The JE vaccines have been mandatory for newborn children to ensure maximum immunisation. Manufacturers catering to the region will have incredible opportunities because of this. Furthermore, increased investment in R&D, the entry of new vaccine manufacturers in countries such as India and China, and an increase in the number of travellers in the region and medical tourism are all contributing to the region's market growth.

Competitive Landscape

The global encephalitis vaccines market is moderately competitive with mergers, collaborations, and product launches. Some of the key players are Valneva SE., Bharat Biotech, BIKEN, Sanofi Pasteur

Pfizer Inc.

Overview: Pfizer Inc., headquartered on 42nd Street in Manhattan, New York City, is an American multinational pharmaceutical and biotechnology corporation. The business was founded in 1849.

Product Portfolio: Pfizer's TBE (Tick-borne encephalitis) vaccine, known in Europe as FSME-Immun and TicoVacand in the United States as TICOVAC, is based on a master'seed' virus that is like the TBE virus found in nature. Because the sequence and structure of the virus subtype match those found in nature, it can induce neutralising antibodies against the natural TBE virus.

Key Development: On 13th August 2021, The US Food and Drug Administration (FDA) approved TICOVAC (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. TICOVAC is the only FDA-approved vaccine for adults and children in the United States who are travelling to or living in TBE-endemic areas.

Why Purchase the Report?

Visualize the composition of the global encephalitis vaccines market segmentation by vaccine type, by type of indication, and end-user highlighting the key commercial assets and players.

Identify commercial opportunities in global encephalitis vaccines market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global encephalitis vaccines market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global encephalitis vaccines market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Encephalitis Vaccines Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Encephalitis Vaccines Market- Market Definition and Overview

3. Encephalitis Vaccines Market- Executive Summary

• 3.1. Market Snippet By Vaccine Type
• 3.2. Market Snippet By Type of Indication
• 3.3. Market Snippet By End User
• 3.4. Market Snippet By Region

4. Encephalitis Vaccines Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The increasing awareness of encephalitis
  • 4.1.2. Restraints:
    • 4.1.2.1. The side effects associated with encephalitis vaccines
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Encephalitis Vaccines Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Encephalitis Vaccines Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Encephalitis Vaccines Market- By Vaccine Type

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
• 7.3. Market Attractiveness Index, By Vaccine Type
  • 7.3.1. Mouse Brain-Derived, Inactivated Vaccine*
    • 7.3.1.1.1. Introduction
    • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3.2. Cell Culture-Derived, Inactivated Vaccine
  • 7.3.3. Cell Culture-Derived, Live Attenuated Vaccine

8. Encephalitis Vaccines Market-By Type of Indication

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Indication
• 8.3. Market Attractiveness Index, By Type of Indication
  • 8.3.1. Japanese Encephalitis
    • 8.3.1.1.1. Introduction
    • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3.2. Tick-Borne Encephalitis
  • 8.3.3. Rabies Encephalitis
  • 8.3.4. Other

9. Encephalitis Vaccines Market- By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Vaccination Centers
• 9.4. Other

10. Encephalitis Vaccines Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Indication
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Indication
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Indication
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Indication
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Indication
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Encephalitis Vaccines Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Encephalitis Vaccines Market- Company Profiles

• 12.1. Pfizer Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Valneva SE
• 12.3. Bharat Biotech
• 12.4. BIKEN
• 12.5. Sanofi Pasteur

LIST NOT EXHAUSTIVE

13. Encephalitis Vaccines Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us